NFL Biosciences announces that it has obtained financing for a total of 1.7 million euros, granted by Bpifrance and financed by the government as part of the Future Investments Program. This biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, and in particular for smoking cessation, announces that its cash horizon “now extends until the end of the third quarter of 2024” after the success of its capital increase of approximately 3 million euros at the end of January.
“We have the appropriate resources to reach the key validation milestones of our two main clinical programs on NFL-101 in the 3rd and 4th quarters of 2023, and to advance in the development of NFL-301”, specifies Ignacio Faus, Chief Executive Officer.
